The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and/or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.
Nucleophilic ring-opening of activated aziridines: A one-step method for labeling biomolecules with fluorine-18
作者:Ulrike Roehn、Jessica Becaud、Linjing Mu、Ananth Srinivasan、Timo Stellfeld、Ansgar Fitzner、Keith Graham、Ludger Dinkelborg、August P. Schubiger、Simon M. Ametamey
DOI:10.1016/j.jfluchem.2009.07.003
日期:2009.10
The direct labeling of biomolecules with fluorine-18 is highly desirable. An option is the ring-opening of an activated aziridine moiety in a biomolecule using (18)F-fluoride. Therefore, a series of aziridine-based model compounds and three aziridine-based biomolecules four aziridine-based model compounds were synthesized and evaluated as potential precursors for a direct one-step radiolabeling with fluorine-18. High to moderate yields of (18)F-incorporation were achieved under mild labeling conditions. The influence of different activating groups, reaction temperature, solvent and base was investigated. The applicability of this method for the direct (18)F-radiolabeling of biomolecules for positron emission tomography (PET) studies is illustrated with examples. (C) 2009 Elsevier B.V. All rights reserved.
Thymidine analogs for imaging
申请人:Bayer Schering Pharma Aktiengesellschaft
公开号:EP1916003A1
公开(公告)日:2008-04-30
The present invention relates to nucleoside analogues and more particularly to labelled nucleoside analogues of formula (I). It has been found new thymidine analogues can be stably labelled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and I or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.